## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

No clear thesis: MRS_10 at 4.9%, does not meet entry criteria. Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($263.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 1)

**1. CI STOCK ALERT: Levi & Korsinsky Notifies The Cigna Group Investors of an Ongoing Investigation**
- Source: ACCESS Newswire | 20251215T140756 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE:CI) for potential federal securities law violations. This investigation follows CI's third-quarter 2025 earnings report, which revealed an increase in their Healthcare MCR to 84.8% from 82.8% in 2024, attributed to their Individual and Family Plans business and higher stop loss medical costs. This news led to a 17% drop in CI's stock price on October 30, 2025.

**2. Rep. Julie Johnson Sells Off Shares of Walmart Inc. (NASDAQ:WMT)**
- Source: MarketBeat | 20251215T101106 | Neutral | Relevance: 75%
- Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 worth of Walmart stock on November 13th, as disclosed in a December 11th filing. This sale was part of several recent transactions where Rep. Johnson also divested shares in other major companies including Charles Schwab, UnitedHealth Group, and Capital One Financial. The article details Walmart's recent stock performance, earnings, analyst ratings, and other insider trading activities.

**3. Rep. Julie Johnson Sells Off Shares of Merck & Co., Inc. (NYSE:MRK)**
- Source: MarketBeat | 20251215T102441 | Somewhat-Bearish | Relevance: 74%
- Representative Julie Johnson (D-Texas) sold between $1,001 and $15,000 of Merck & Co., Inc. (NYSE:MRK) stock on November 13th, a transaction disclosed on December 11th. This was part of a series of similar sales she made in several large companies including Charles Schwab, UnitedHealth, and Goldman Sachs on the same day. Merck recently reported strong quarterly earnings, setting positive FY2025 guidance and increasing its quarterly dividend.

**4. Rep. Julie Johnson Sells Philip Morris International Inc. (NYSE:PM) Shares**
- Source: MarketBeat | 20251215T132136 | Neutral | Relevance: 74%
- Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 worth of Philip Morris International Inc. (NYSE:PM) shares on November 13th, as disclosed in a December 11th filing. She also sold similar amounts of shares in several other major companies on the same date. The article provides a financial overview of Philip Morris International, including its market performance, recent earnings, dividend announcement, and institutional investor activity, alongside analyst ratings.

**5. Rep. Julie Johnson Unloads McDonald's Corporation (NYSE:MCD) Stock**
- Source: MarketBeat | 20251215T132127 | Neutral | Relevance: 73%
- Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 in McDonald's Corporation (NYSE:MCD) stock on November 13th, 2025, according to a December 11th filing. She also sold shares of several other companies, including Charles Schwab, UnitedHealth Group, and Walmart, within the same value range on the same date. The article provides an overview of McDonald's stock performance, recent earnings, dividend increase, and analyst ratings, alongside insider trading activities and institutional ownership changes.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 8.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +8.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.55 indicates undervaluation relative to growth. Forward P/E 9.1x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $74.0B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.55 |
| Forward P/E | 9.1 |
| Current P/E | 9.4 |
| YoY Growth | 3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.6% to 4.9% (+8.4% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 4.3% confirms short-term momentum alignment. Outperforming sector by 3.4pp, stock-specific strength. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (1.13), confirming momentum. RSI neutral at 54. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.87% (CS: 84) | Strong |
| RSI_14 | 54.5 | Neutral |
| MACD Histogram | 1.13 | Bullish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 0.916x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $277.15
- **Stop Loss:** $263.67 (4.9% risk)
- **Target:** $290.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 89
- **Position Value:** $24,666.35
- **Portfolio %:** 24.67%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*